Get started
Author

Darren Leaning

Observed names: D Leaning, D. Leaning, D.J. Leaning, Darren James Leaning, Leaning D, Leaning, D, Leaning, Darren
Observed institutions: Belfast Health and Social Care Trust, University Hospitals Birmingham NHS Foundation Trust, Royal Victoria Infirmary, James Cook University Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, South Tees Hospitals NHS Foundation Trust, Public Health England, National Institute for Health and Care Research, University of Oxford, Sheffield Teaching Hospitals NHS Foundation Trust, Public Health Scotland, National Records of Scotland, Newcastle upon Tyne Hospital, Nepal Health Research Council, Oxford University Clinical Research Unit, Intensive Care National Audit & Research Centre, Oxford University Clinical Research Unit Indonesia, Newcastle University
OpenAlex ID: A5060935233
Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
2021 · Eugenia Abaleke, Mustafa Abbas, et al. · The Lancet · 533
PDF
Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial
2021 · Obbina Abani, Ali Abbas, et al. · The Lancet · 493
Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
2022 · Obbina Abani, Ali Abbas, et al. · The Lancet · 369
Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis
2022 · Obbina Abani, Ali Abbas, et al. · The Lancet · 324
Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
2021 · Obbina Abani, Ali Abbas, et al. · The Lancet · 290
Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial
2023 · Obbina Abani, Ali Abbas, et al. · The Lancet · 129
Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol
2023 · Gerhardt Attard, Laura Murphy, et al. · The Lancet Oncology · 118
PDF
Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
2023 · O Abani, A Abbas, et al. · The Lancet Diabetes & Endocrinology · 41
PDF
Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial
2024 · Saul N Faust, Richard Haynes, et al. · The Lancet Child & Adolescent Health · 39
PDF
Treatment landscape and burden of disease in metastatic castration-resistant prostate cancer: systematic and structured literature reviews
2023 · Darren Leaning, Gagandeep Kaur, et al. · Frontiers in Oncology · 22
Eligibility for 177 Lu-PSMA Therapy Depends on the Choice of Companion Diagnostic Tracer: A Comparison of 68 Ga-PSMA-11 and 99m Tc-MIP-1404 in Metastatic Castration-Resistant Prostate Cancer
2022 · Gary J.R. Cook, Wai-Lup Wong, et al. · Journal of Nuclear Medicine · 21
PDF
Optimising Radium 223 Therapy for Metastatic Castration-Resistant Prostate Cancer –5-year Real-World Outcome: Focusing on Treatment Sequence and Quality of Life
2020 · X.Y. Jiang, S. Atkinson, et al. · Clinical Oncology · 18
Molnupiravir or nirmatrelvir–ritonavir plus usual care versus usual care alone in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
2025 · O Abani, A Abbas, et al. · The Lancet Infectious Diseases · 12
PDF
The Current Views of Clinical Oncology Trainees
2014 · J. Said, D.K. Woolf, et al. · Clinical Oncology · 9
On-treatment serum prostate-specific antigen and overall survival in prostate cancer (STAMPEDE platform protocol): a post-hoc analysis of data from five phase 3 trials
2026 · Mahaz Kayani, Laura Murphy, et al. · The Lancet Oncology · 6
PDF
Plasma AR Alterations and Timing of Intensified Hormone Treatment for Prostate Cancer
2025 · Gianmarco Leone, Francesco Orlando, et al. · JAMA Oncology · 5
Higher dose corticosteroids in hospitalised COVID-19 patients requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial
2025 · O. Abani, A. Abbas, et al. · EClinicalMedicine · 5
Non-traumatic gas gangrene presenting as left buttock and thigh pain in a patient with metastatic non-small cell lung cancer: Figure 1
2010 · Darren James Leaning, Lynne Dixon, et al. · BMJ Case Reports · 5
PDF
Human Papillomavirus–Associated Multiphenotypic Carcinoma: First Description of a Vulval Case
2024 · Charlotte C. Currie, Darren Leaning, et al. · International Journal of Gynecological Pathology · 3
Cortical Blindness as an Unusual Adverse Drug Reaction
2010 · Caroline Wilson, Darren Leaning, et al. · Journal of Medical Cases · 2
National small cell bladder cancer audit: Results from 26 UK institutions
2019 · C. Chau, Y. Rimmer, et al. · Annals of Oncology · 1
PDF
476 Palliative Radiotherapy in Patients with Metastatic Breast Cancer–Rates of Utilization, Distance Travelled and Incurred Costs
2012 · D. Leaning, M. Kagzi, et al. · European Journal of Cancer · 1
Stereotactic Ablative Radiotherapy for Stage 1 renal cell carcinoma: A single-centre experience
2026 · Robin Inkersole, Darren Leaning, et al. · Clinical Oncology
Healthcare professionals' outlook on apalutamide for metastatic hormone sensitive prostate cancer within the ADAPT-P study
2025 · C. Thompson, A. Tree, et al. · European Urology Open Science
Sotrovimab versus usual care in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
2025 · O Abani, A Abbas, et al. · The Lancet Infectious Diseases
PDF
Works count: 36
Citation count: 2,444
H-index: 12
I10-index: 13
Year
Topic
Type